Dupixent CTCL MDL 3180: Build the Timeline Before Records Get Hard to Find

If Dupixent is part of your family's CTCL story, the first job is not to
guess what happened. It is to pin down dates.

That may sound basic. In real life, it is usually messy. A rash starts in
one doctor's chart. A biopsy is done months later. A specialist changes
the diagnosis. Pharmacy records sit in a different portal. A family member
remembers the itching got worse after injections started, but no one wrote
the exact month down.

Those details matter now because the federal Dupixent CTCL cases have been
grouped in one court.

On June 4, 2026, the Judicial Panel on Multidistrict Litigation created
MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation.
The cases were transferred to the District of New Jersey and assigned to
Judge Zahid N. Quraishi.

The JPML's transfer order said most plaintiffs used Dupixent for atopic
dermatitis, commonly known as eczema, and were later diagnosed with
cutaneous T-cell lymphoma, or CTCL. Some claims were brought by spouses or
survivors. The Panel also noted seven potential tag-along actions at the
time of transfer.

That order did not decide whether Dupixent caused anyone's cancer. It did
something narrower. It put similar federal cases before one judge because
they raise shared questions about science, warnings, company knowledge,
and patient history.

For patients and families, the practical takeaway is simple: preserve the
medical trail while it is still reachable.

Start with the before-and-after picture

The allegations in the MDL include claims that Dupixent caused CTCL or
accelerated a CTCL that was already present. Those are different medical
and legal questions.

A reviewer will usually want to know what the skin condition looked like
before Dupixent, why the drug was prescribed, what happened after
treatment began, and when CTCL first appeared in the record. The answer
may be spread across years of notes.

Try to gather:

• the first Dupixent prescription date and dose;
• refill records or injection logs;
• dermatology notes from before Dupixent was started;
• photos of rashes, plaques, patches, or lesions, if they are dated;
• all biopsy reports, including older reports that did not diagnose CTCL;
• pathology addenda or outside pathology reviews;
• oncology, hematology, or radiation oncology records;
• CTCL subtype and staging information, if your doctor documented it;
• patient portal messages about worsening symptoms; and
• insurance or pharmacy benefit records showing fills and denials.

Do not worry if the packet is ugly at first. A folder full of imperfect
records is better than a clean summary that leaves out the key dates.

Ask for the complete chart, not just visit notes

Many patient portals show only part of the file. They may leave out
pathology attachments, referral letters, scanned outside records, old
medication lists, or photos taken by the clinic.

When you request records, use plain language. Ask for the complete
dermatology chart, complete pathology file, complete medication history,
and any outside records received from other providers. If there were
several dermatologists, request records from each office.

Pathology deserves special attention. CTCL cases can involve more than one
biopsy before the diagnosis is clear. If the first report said eczema,
dermatitis, atypical lymphoid infiltrate, mycosis fungoides, Sezary
syndrome, or another T-cell lymphoma term, keep the full report. Do not
rely on memory or a one-line portal result.

What the MDL numbers show so far

The MDL is young. At transfer, the JPML described fifteen actions and
seven potential tag-along actions across twelve districts. The July 1,
2026 JPML pending-MDL report listed MDL 3180 with 26 pending actions and
27 total actions.

Those numbers are not settlement numbers. They are not predictions. They
simply show that more cases were already moving into the centralized
proceeding during the first month.

The JPML also left one issue open. Defendants asked the Panel to limit the
MDL to CTCL cases. Plaintiffs argued that other T-cell lymphoma subtypes
could overlap with the same evidence. The Panel did not decide that
broader question at the transfer stage and said future expansion could be
addressed through the conditional transfer process.

That is another reason the exact diagnosis matters. CTCL, peripheral
T-cell lymphoma, anaplastic large cell lymphoma, and other lymphoma labels
should not be mixed together casually. The words in the pathology report
matter.

The label does not answer every question

Dupixent remains an FDA-approved prescription drug. The April 2026 FDA
prescribing information lists Dupixent as an interleukin-4 receptor alpha
antagonist and includes several approved uses, including atopic
dermatitis.

The current label is only one piece of the picture. MDL discovery can look
at medical literature, adverse-event information, company communications,
warning decisions, and patient-specific records. Families should avoid
making medical assumptions from the existence of the MDL alone.

If you are still using Dupixent, do not stop a prescribed medication based
on an internet article. Talk with your doctor about symptoms, diagnosis
questions, and treatment choices.

When a family should ask questions

A legal screening may make sense when someone used Dupixent and later
received a CTCL diagnosis, when a loved one died after a CTCL diagnosis,
or when records suggest a T-cell lymphoma was suspected after Dupixent
treatment. A screening is not a promise that a claim exists. It is a way
to check exposure dates, diagnosis, records, and filing deadlines before
time passes.

One small step today can help: write down the timeline in ordinary
language. When did the skin problem begin? When did Dupixent start? When
did symptoms change? When was the first biopsy? When did a doctor first
say CTCL? Then match that timeline to records as they arrive.

This article is attorney advertising and is for informational purposes
only. It is not medical advice, and it does not create an attorney-client
relationship. Past results do not guarantee future outcomes. If you have
medical concerns, speak with your doctor. If you have legal questions,
speak with a lawyer about your specific facts and deadlines.